AngioDynamics Statistics
Total Valuation
AngioDynamics has a market cap or net worth of $506.02 million. The enterprise value is $450.11 million.
Important Dates
The last earnings date was Wednesday, January 8, 2025, before market open.
| Earnings Date | Jan 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
AngioDynamics has 40.47 million shares outstanding. The number of shares has increased by 1.91% in one year.
| Current Share Class | 40.47M |
| Shares Outstanding | 40.47M |
| Shares Change (YoY) | +1.91% |
| Shares Change (QoQ) | +0.66% |
| Owned by Insiders (%) | 3.39% |
| Owned by Institutions (%) | 74.14% |
| Float | 36.84M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.73 |
| Forward PS | 1.69 |
| PB Ratio | 2.67 |
| P/TBV Ratio | 4.44 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.57 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.98
| Current Ratio | 1.98 |
| Quick Ratio | 1.10 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -76.44% and return on invested capital (ROIC) is -7.63%.
| Return on Equity (ROE) | -76.44% |
| Return on Assets (ROA) | -5.71% |
| Return on Capital (ROIC) | -7.63% |
| Revenue Per Employee | $383,019 |
| Profits Per Employee | -$300,429 |
| Employee Count | 748 |
| Asset Turnover | 0.72 |
| Inventory Turnover | 2.08 |
Taxes
| Income Tax | -12.67M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +106.15% in the last 52 weeks. The beta is 0.59, so AngioDynamics's price volatility has been lower than the market average.
| Beta (5Y) | 0.59 |
| 52-Week Price Change | +106.15% |
| 50-Day Moving Average | 9.17 |
| 200-Day Moving Average | 7.33 |
| Relative Strength Index (RSI) | 66.09 |
| Average Volume (20 Days) | 910,150 |
Short Selling Information
The latest short interest is 822,906, so 2.03% of the outstanding shares have been sold short.
| Short Interest | 822,906 |
| Short Previous Month | 882,005 |
| Short % of Shares Out | 2.03% |
| Short % of Float | 2.23% |
| Short Ratio (days to cover) | 1.80 |
Income Statement
In the last 12 months, AngioDynamics had revenue of $286.50 million and -$224.72 million in losses. Loss per share was -$5.55.
| Revenue | 286.50M |
| Gross Profit | 151.01M |
| Operating Income | -36.13M |
| Pretax Income | -191.64M |
| Net Income | -224.72M |
| EBITDA | -10.54M |
| EBIT | -36.13M |
| Loss Per Share | -$5.55 |
Full Income StatementBalance Sheet
| Cash & Cash Equivalents | 54.09M |
| Total Debt | n/a |
| Net Cash | 54.09M |
| Net Cash Per Share | $1.34 |
| Equity (Book Value) | 186.77M |
| Book Value Per Share | 4.57 |
| Working Capital | 86.77M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$23.31 million and capital expenditures -$3.06 million, giving a free cash flow of -$26.37 million.
| Operating Cash Flow | -23.31M |
| Capital Expenditures | -3.06M |
| Free Cash Flow | -26.37M |
| FCF Per Share | -$0.65 |
Full Cash Flow StatementMargins
Gross margin is 52.71%, with operating and profit margins of -12.61% and -78.44%.
| Gross Margin | 52.71% |
| Operating Margin | -12.61% |
| Pretax Margin | -82.86% |
| Profit Margin | -78.44% |
| EBITDA Margin | -3.68% |
| EBIT Margin | -12.61% |
| FCF Margin | n/a |